Aging intervertebral discs are a major contributor to chronic low back pain, yet the biological chain of events that turns tissue aging into degeneration remains difficult to interrupt. In a new open-access study in Aging, researchers tested a next-generation senolytic PROTAC designed to eliminate therapy-resistant cellular stress states tied to aging-related inflammation.
The compound, PROTAC 753b, works by using a dual binding moiety to bring the anti-apoptotic proteins BCL-2 and BCL-xL into proximity with the VHL E3 ligase. Once recruited, the target proteins are ubiquitinated and degraded by the proteasome. This approach aims to trigger apoptosis preferentially in senescent or survival-dependent cells while addressing platelet toxicity concerns associated with earlier BCL-2/BCL-xL-targeting strategies.
To evaluate therapeutic impact, investigators administered PROTAC 753b systemically to aged mice beginning at 16 months of age. The regimen comprised six one-month cycles, each separated by drug delivery and rest periods; dosing occurred twice per week via intraperitoneal injection at 5 mg/kg. Discs were analyzed after six months of treatment, when animals reached 22 months of age.
Histological and molecular analyses focused on hallmarks of intervertebral disc degeneration, including extracellular matrix integrity and protease-driven breakdown. In male mice, PROTAC 753b substantially preserved disc structure, maintaining aggrecan and reducing MMP-associated aggrecan degradation—changes consistent with a slower pace of age-driven tissue deterioration.
Surprisingly, the benefits were largely absent in female mice. This sex-specific outcome suggests that disc degeneration trajectories differ by sex at this life stage, potentially altering both the burden of vulnerable cells and the baseline inflammatory environment that therapy can modulate.
Mechanistic probing of cellular senescence markers inside disc tissue did not show the expected drop in canonical senescence signatures, nor did it clearly shift PROTAC molecular targets within the disc microenvironment. Instead, treated male animals displayed lower circulating inflammatory proteins such as IL-6 and TNFα, pointing toward a dominant systemic, non-cell-autonomous mechanism.
The authors also argue that effective senolytic action may not require high intradisc drug penetration. Because intervertebral discs are largely avascular, local drug delivery can be limited; nonetheless, systemic reduction of senescence-associated inflammation may still translate into measurable structural rescue.
Together, the study positions PROTAC 753b as a viable strategy to ameliorate age-related intervertebral disc degeneration, at least in males, while highlighting a critical variable for translation: sex-dependent biology may govern whether global senolytic immunometabolic effects reach clinically meaningful outcomes.
Finally, the work underscores both opportunity and uncertainty in targeting senescence networks. If systemic inflammatory tone can be recalibrated, disc aging may be slowed even when local target engagement is incomplete—an idea that will require follow-up studies in additional models and, ultimately, human trials.
Subject of Research: Animals (intervertebral disc aging; cellular senescence)
Article Title: Slowing intervertebral disc aging in mice through long-term systemic treatment with the senolytic BCL-2/BCL-xL proteolysis targeting chimera (PROTAC) 753b
News Publication Date: 13-Jul-2026
Web References: https://doi.org/10.18632/aging.206394
References: https://doi.org/10.18632/aging.206394
Image Credits: Copyright: © 2026 Alexander et al. (CC BY 4.0)
Keywords: intervertebral disc aging, cellular senescence, senolytic, anti-apoptosis, PROTAC-753b
